

CORRECTION

Open Access



# Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Jia Yu<sup>1</sup>, Bo Qin<sup>1,2</sup>, Ann M. Moyer<sup>3</sup>, Jason P. Sinnwell<sup>4</sup>, Kevin J. Thompson<sup>4</sup>, John A. Copland III<sup>5</sup>, Laura A. Marlow<sup>5</sup>, James L. Miller<sup>5</sup>, Ping Yin<sup>2</sup>, Bowen Gao<sup>13</sup>, Katherine Minter-Dykhouse<sup>2</sup>, Xiaojia Tang<sup>4</sup>, Sarah A. McLaughlin<sup>6</sup>, Alvaro Moreno-Aspitia<sup>7</sup>, Anthony Schweitzer<sup>8</sup>, Yan Lu<sup>8</sup>, Jason Hubbard<sup>8</sup>, Donald W. Northfelt<sup>9</sup>, Richard J. Gray<sup>10</sup>, Katie Hunt<sup>11</sup>, Amy L. Conners<sup>11</sup>, Vera J. Suman<sup>4</sup>, Krishna R. Kalari<sup>4</sup>, James N. Ingle<sup>2</sup>, Zhenkun Lou<sup>2</sup>, Daniel W. Visscher<sup>3</sup>, Richard Weinsilboum<sup>1</sup>, Judy C. Boughey<sup>12</sup>, Matthew P. Goetz<sup>1,2</sup> and Liewei Wang<sup>1\*</sup>

**Correction to: Breast Cancer Research 19, 130 (2017)**  
<http://dx.doi.org/10.1186/s13058-017-0920-8>

Following publication of the original article [1], the authors would like to correct several typos in the article text:

- 1) Page 4-right panel, Line 10: “The take rate was 51.3% (21/39; 95% CI: 34.8-67.6%) in TN subtype;”. Take rate should be **20/39** not 21/39. Percentages are correct.
- 2) Page 4-right panel, Line 21: The last 2 sentences were corrected to be consistent with Table 2 as follows: “There was no take among the 18 luminal tumors. However, five of nine TN, and one of the eight HER2+ post-chemotherapy residual tumors took (verified breast tumor).”

- 3) Page 4-right panel, Table 2: Total implanted for Luminal B should be **14** instead of 18. The total number of implanted 35 was correct.
- 4) Page 5-left panel, Line 15: HER2+ tumors (7/17 vs. 2/15) should be (7/**19** vs. 2/15). *P*-value is correct.
- 5) Page 5-left panel, Line 20, The number of luminal tumors should be 18 instead of 22.

The authors sincerely apologize for any inconvenience.

#### Author details

<sup>1</sup>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. <sup>2</sup>Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. <sup>3</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA. <sup>4</sup>Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA. <sup>5</sup>Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA. <sup>6</sup>Department of Surgery, Mayo Clinic, Jacksonville, FL 32224, USA. <sup>7</sup>Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. <sup>8</sup>Affymetrix, now part of Thermo Fisher Scientific, Santa Clara, CA 95051, USA. <sup>9</sup>Department of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA. <sup>10</sup>Department of Surgery, Mayo Clinic, Scottsdale, AZ 85259, USA. <sup>11</sup>Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. <sup>12</sup>Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.

The original article can be found online at <https://doi.org/10.1186/s13058-017-0920-8>.

\* Correspondence: [Wang.Liewei@mayo.edu](mailto:Wang.Liewei@mayo.edu)

<sup>1</sup>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA  
Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>13</sup>Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Published online: 25 March 2021

#### Reference

1. Yu, et al. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. *Breast Cancer Research*. 2017;19:130. <https://doi.org/10.1186/s13058-017-0920-8>.